What Is Saxenda? Uses, Dosing and Side Effects

Saxenda is a prescription injectable medicine used for chronic weight management in adults and certain adolescents in the UK. Containing liraglutide 6 mg/mL, it works by mimicking the gut hormone GLP-1 to reduce appetite, slow stomach emptying and help regulate blood glucose. Licensed by the MHRA and recommended by NICE, Saxenda is used alongside a reduced-calorie diet and exercise programme. This article explains how Saxenda works, who qualifies for it on the NHS, how to use the pen correctly, and which side effects to monitor during treatment.

What is Saxenda and how does it work in the body?

Saxenda is a GLP-1 receptor agonist containing liraglutide that reduces appetite, slows gastric emptying and regulates blood glucose; it is MHRA-licensed for chronic weight management and must be used alongside diet and exercise.

Saxenda is a prescription-only injectable medicine containing liraglutide 6 mg/mL, supplied as a multi-dose pre-filled pen. The usual maintenance dose is 3 mg once daily. Saxenda is licensed by the MHRA for chronic weight management in adults and, under specific criteria set out in the UK Summary of Product Characteristics (SmPC), in adolescents aged 12 to 17 with obesity and weight-related comorbidities.

Liraglutide belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is a hormone produced naturally in the gut after eating, and Saxenda works by mimicking its effects in the body.

Once injected, liraglutide binds to GLP-1 receptors in several areas, including the brain's appetite-regulating centres, the stomach and the pancreas. This produces three main effects: it slows the rate at which the stomach empties food into the small intestine, it reduces appetite by signalling a feeling of fullness to the brain, and it helps regulate blood glucose levels by stimulating insulin release in a glucose-dependent manner. Together, these actions support a reduction in calorie intake and, over time, body weight.

It is important to understand that Saxenda is not a replacement for a healthy diet and increased physical activity. It is intended to be used alongside a reduced-calorie diet and exercise programme as part of a structured weight management plan. Saxenda is a different product from Victoza, which contains the same active ingredient (liraglutide) at a lower dose and is licensed specifically for type 2 diabetes management.^[9][3] The two products are not interchangeable.

Who is Saxenda prescribed for on the NHS?

NICE TA664 recommends NHS Saxenda for adults with a BMI of 35 kg/m² or above plus a weight-related comorbidity, accessed through specialist weight management services, with a mandatory 16-week stopping rule if less than 5% weight loss is achieved.

NHS access to Saxenda is governed by NICE Technology Appraisal TA664, which recommends liraglutide 3 mg for weight management in adults when used within specialist weight management services. The criteria include a BMI of 35 kg/m² or above alongside at least one weight-related comorbidity, or a BMI of 30 to 34.9 kg/m² in certain higher-risk groups. Lower BMI thresholds apply for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean family background, in line with NICE guidance on ethnicity-adjusted thresholds.^[10][2]

TA664 also specifies a stopping rule: treatment should be reviewed at 16 weeks. If a patient has not lost at least 5% of their initial body weight by that point, Saxenda should be discontinued, as continued treatment is unlikely to be beneficial.

For adolescents aged 12 to 17, Saxenda holds a UK marketing authorisation for weight management under specific criteria defined in the SmPC. NHS commissioning for this age group is subject to local Integrated Care Board (ICB) decisions and specialist service availability; patients and families should discuss eligibility with their clinical team.

NHS availability is not automatic following a NICE technology appraisal. Local ICBs make commissioning decisions, and access through NHS specialist services may vary by region. Patients are typically referred by their GP to a tier 3 or tier 4 specialist weight management service, where Saxenda may be considered as part of a broader programme including dietary, behavioural and physical activity support.

For those who do not meet NHS criteria or who prefer to access treatment privately, online consultations with a registered provider are an option. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering weight management consultations, with prescriber review and pharmacist support, where a medicine such as Saxenda may be considered if it is clinically appropriate following consultation. Treatment should always be initiated and monitored by a qualified prescriber, and patients should continue to be reviewed regularly to assess progress and tolerability.

How do you use the Saxenda pen and what dose will you start on?

Saxenda is injected subcutaneously once daily, starting at 0.6 mg and increasing weekly over five weeks to the 3.0 mg maintenance dose; injection sites should be rotated and the pen stored in a refrigerator before first use.

Saxenda is supplied as a pre-filled, multi-dose injection pen and is administered as a subcutaneous (under the skin) injection once daily. The injection can be given at any time of day, with or without food, but it is helpful to choose a consistent time each day to build a routine. Suitable injection sites include the abdomen, the front of the thigh or the upper arm, and the site should be rotated with each injection to reduce the risk of skin reactions.

Dosing follows a structured escalation schedule to help minimise gastrointestinal side effects. Treatment begins at 0.6 mg once daily for the first week. The dose is then increased in weekly steps:

• Week 1: 0.6 mg daily

• Week 2: 1.2 mg daily

• Week 3: 1.8 mg daily

• Week 4: 2.4 mg daily

• Week 5 onwards: 3.0 mg daily (the usual maintenance dose)

If a patient cannot tolerate a dose increase, the prescriber may advise remaining at the current dose for an additional week before escalating further.

If you miss a dose, take it as soon as you remember, provided the next scheduled dose is at least 12 hours away.^[6][7] If fewer than 12 hours remain before your next dose, skip the missed dose and continue with your usual schedule. Do not take two doses to make up for a missed one. If you have missed several days of treatment, contact your prescriber before restarting, as dose re-escalation may be needed.

The pen requires a new needle to be attached for each injection; needles are not included in the pack and must be obtained separately. For full step-by-step injection technique, including the flow check, needle handling and sharps disposal, follow the official Instructions for Use supplied with your pen. Do not share your pen with anyone else, even if the needle is changed, as this carries a risk of infection.

Saxenda pens should be stored in a refrigerator (2°C to 8°C) before first use. After first use, the pen can be kept at room temperature (not above 30°C) or in the refrigerator for up to 30 days. Always follow the storage instructions in the patient information leaflet supplied with your medicine.

What side effects should you watch out for with Saxenda?

The most common side effects are gastrointestinal, including nausea and vomiting, which typically improve over time; serious risks include acute pancreatitis, gallbladder problems and hypoglycaemia, all requiring prompt medical attention.

The most commonly reported side effects with Saxenda are gastrointestinal in nature, and these are most likely to occur during the dose escalation phase. They include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. For most people, these effects are mild to moderate and tend to improve as the body adjusts to the medicine over several weeks. Taking Saxenda at a consistent time and eating smaller, lower-fat meals can help reduce nausea.

More serious side effects, though less common, require prompt medical attention:

• Pancreatitis: Acute pancreatitis has been reported with liraglutide, including post-marketing reports of necrotising pancreatitis and cases with a fatal outcome.^[11][1] Persistent, severe abdominal pain that may radiate to the back, with or without vomiting, should be assessed urgently. If pancreatitis is suspected, stop taking Saxenda and seek medical advice immediately. If pancreatitis is confirmed, Saxenda must not be restarted. Contact NHS 111 or attend A&E if the pain is severe.

• Dehydration and kidney effects: Severe vomiting or diarrhoea can lead to dehydration, which may affect kidney function. Drink plenty of fluids if you experience these symptoms. If you are unable to keep fluids down, seek medical advice promptly.

• Gallbladder problems: Cholelithiasis (gallstones) and cholecystitis have been reported.^[1][12] Symptoms include upper abdominal pain, fever and jaundice.

• Heart rate: An increase in resting heart rate has been observed; this should be discussed with a prescriber if noticed.^[1][14]

• Hypoglycaemia: Low blood sugar is more likely if Saxenda is used alongside other glucose-lowering medicines, particularly sulfonylureas or insulin. Your prescriber may need to review and adjust the doses of those medicines.

• Mental health: The UK SmPC for Saxenda includes a caution regarding mood changes. If you notice any changes in mood, feelings of depression, or thoughts of self-harm, contact your GP or a healthcare professional promptly.

Saxenda must not be used during pregnancy or breastfeeding.^[1][7] Women of childbearing potential should use effective contraception while taking Saxenda, and the medicine should be stopped if pregnancy is confirmed or planned. Contact your GP promptly if you become pregnant during treatment.

Saxenda should not be used at the same time as other GLP-1 receptor agonists or other prescription weight-loss medicines, as this combination is not recommended.

If you experience a suspected side effect, this can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you feel unwell in a way that concerns you, contact your GP or call NHS 111 for advice.

Scientific References

1. Saxenda 6 mg/mL solution for injection in pre-filled pen – Summary of Product Characteristics.
2. Liraglutide for managing overweight and obesity (Technology Appraisal TA664).
3. Liraglutide: a medicine to treat type 2 diabetes or obesity.
4. Saxenda – European Public Assessment Report.
5. Liraglutide – British National Formulary (BNF/NICE).
6. Saxenda, INN-liraglutide – Product Information (EMA).
7. Saxenda 6 mg/mL – Patient Information Leaflet (EMC).
8. Liraglutide for managing overweight and obesity – Evidence document (TA664).
9. Victoza – European Public Assessment Report.
10. Overweight and obesity management (NG246) – Identifying and assessing overweight, obesity and central adiposity.
11. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
12. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
13. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
14. Heart rate increases in liraglutide treated chronic heart failure patients.
15. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.

Frequently Asked Questions